Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.50 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.50 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639788 | 0.82 | P2RX3 (0.47) | QPCTQPCTLP2RX3FTOPPARD | |
| SCHEMBL14466720 | 0.79 | QPCT (0.50) | QPCTQPCTLP2RX3PPARDNPSR1 | |
| SCHEMBL2759587 | 0.78 | QPCT (0.52) | QPCTQPCTLP2RX3PPARDNPSR1 | |
| SCHEMBL1639921 | 0.77 | HRH3 (0.64) | — | |
| SCHEMBL16675754 | 0.76 | QPCT (0.51) | QPCTQPCTLP2RX3PPARDNPSR1 | |
| SCHEMBL19413896 | 0.75 | QPCT (0.47) | QPCTQPCTLP2RX3PPARDNPSR1 | |
| SCHEMBL16104488 | 0.73 | QPCT (0.56) | QPCTQPCTLP2RX3FTOPPARD | |
| SCHEMBL29809511 | 0.72 | HSD11B1 (0.57) | QPCTQPCTLNPSR1ATMMEN1 | |
| SCHEMBL4743846 | 0.72 | HSD11B1 (0.57) | QPCTQPCTLNPSR1ATMMEN1 | |
| SCHEMBL15677872 | 0.72 | PPARD (0.51) | QPCTQPCTLP2RX3PPARDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273767-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-7947711-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-28 | — | — | US | disclosed |
| US-20090054420-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| US-7456196-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-11-25 | — | — | US | disclosed |
| US-7153889-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-08-31 | — | — | US | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | QPCT 1514/4885QPCTL 3326/4885P2RX3 182/4885 |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH2 | QPCT 1514/4885QPCTL 3326/4885P2RX3 182/4885 |
| US-20090054420-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | QPCT 1514/4885QPCTL 3326/4885P2RX3 182/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | QPCT 2059/4885QPCTL 3941/4885P2RX3 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.